Wilex receives IND approval from FDA for phase III trial with Rencarex® in renal cell carcinoma

被引：0
|
作者：
Orlowski, J
机构：
来源：
THROMBOSIS AND HAEMOSTASIS | 2004年 / 92卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：VII / VII
页数：1
相关论文
共 50 条
  • [1] Axitinib for the treatment of renal cell carcinoma receives US FDA approval
    Purslow, Caroline
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (03) : 296 - 296
  • [2] Cabozantinib receives Approval Recommendation of the CHMP for the Treatment of the advanced Renal Cell Carcinoma
    Gerwe, Martin
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (09) : 576 - 576
  • [3] FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
    Kwitkowski, Virginia E.
    Prowell, Tatiana M.
    Ibrahim, Amna
    Farrell, Ann T.
    Justice, Robert
    Mitchell, Shan Sun
    Sridhara, Rajeshwari
    Pazdur, Richard
    [J]. ONCOLOGIST, 2010, 15 (04): : 428 - 435
  • [4] FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma
    Chang, Elaine
    Weinstock, Chana
    Zhang, Lijun
    Fiero, Mallorie H.
    Zhao, Miao
    Zahalka, Eias
    Ricks, Tiffany K.
    Zirkelbach, Jeanne Fourie
    Qiu, Junshan
    Yu, Jingyu
    Chen, Xiao Hong
    Bhatnagar, Vishal
    Goldberg, Kirsten B.
    Tang, Shenghui
    Kluetz, Paul G.
    Pazdur, Richard
    Ibrahim, Amna
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (03) : 441 - 445
  • [5] FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
    Summers, Jeff
    Cohen, Martin H.
    Keegan, Patricia
    Pazdur, Richard
    [J]. ONCOLOGIST, 2010, 15 (01): : 104 - 111
  • [6] Sorafenib in advanced renal cell carcinoma (RCC): Survival and biomarker results from a phase III trial
    Bukowski, R.
    Hong, D.
    Eisen, T.
    Szczylik, C.
    Stadler, W. M.
    Porte, C.
    Simantov, R.
    Shan, M.
    Elting, J.
    Pena, C.
    Escudier, B.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 245 - 245
  • [7] Chimeric monoclonal antibody CG250 (Rencarex®) as immunotherapy of renal cell carcinoma:: clinical Phase II summary and current adjuvant Phase III trial in non-metastasized RCC after nephrectomy
    Belldegrun, A
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 18 - 18
  • [8] Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma
    Tsimafeyeu, Ilya
    [J]. KIDNEY CANCER, 2021, 5 (02) : 63 - 71
  • [9] A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients
    M. Siebels
    K. Rohrmann
    R. Oberneder
    M. Stahler
    N. Haseke
    J. Beck
    R. Hofmann
    M. Kindler
    P. Kloepfer
    C. Stief
    [J]. World Journal of Urology, 2011, 29 : 121 - 126
  • [10] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
    Sternberg, Cora N.
    Davis, Ian D.
    Mardiak, Jozef
    Szczylik, Cezary
    Lee, Eunsik
    Wagstaff, John
    Barrios, Carlos H.
    Salman, Pamela
    Gladkov, Oleg A.
    Kavina, Alexander
    Zarba, Juan J.
    Chen, Mei
    McCann, Lauren
    Pandite, Lini
    Roychowdhury, Debasish F.
    Hawkins, Robert E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 1061 - 1068
12345